Teruhisa Takuwa1, Masaki Hashimoto2, Seiji Matsumoto2, Nobuyuki Kondo2, Kozo Kuribayash3, Takashi Nakano3, Seiki Hasegawa2. 1. Department of Thoracic Surgery, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo, 663-8501, Japan. ttakuwa@hyo-med.ac.jp. 2. Department of Thoracic Surgery, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo, 663-8501, Japan. 3. Department of Respiratory Medicine, Hyogo College of Medicine, 1-1 Mukogawacho, Nishinomiya, Hyogo, Japan.
Abstract
BACKGROUND: Additional chemotherapy is often not feasible in patients with recurrent malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP), due to deteriorated cardiopulmonary reserve. We thus examined the feasibility and efficacy of additional chemotherapy in patients with recurrent MPM after EPP. METHODS: A retrospective review was conducted of 59 consecutive patients who underwent bi-/tri-modal treatment with induction chemotherapy, EPP, and radiation therapy from July 2004 to August 2013 at Hyogo College of Medicine (Nishinomiya, Japan). RESULTS: Of 59 patients, 39 (male/female = 31/8, right/left = 15/24, pathological stage I/II/III/IV = 1/7/23/3, bi-/tri-modality = 27/12) relapsed at a median age of 62 (range 37-71) years. The median time to recurrence after EPP was 11.6 months. Of the 39 relapsed patients, 12 received best supportive care alone, six started but discontinued chemotherapy, and the remaining 21 (53%) completed more than three cycles of intravenous chemotherapy. The median survival time after EPP was significantly longer in 21 patients who received additional chemotherapy than in 18 patients who did not (39.2 vs. 12.2 months, P = 0.009). CONCLUSIONS: Additional systemic chemotherapy was successfully administered in more than 50% of relapsed patients after bi-/tri-modal treatment, which included EPP, and resulted in a longer survival in comparison with best supportive care alone.
BACKGROUND: Additional chemotherapy is often not feasible in patients with recurrent malignant pleural mesothelioma (MPM) undergoing extrapleural pneumonectomy (EPP), due to deteriorated cardiopulmonary reserve. We thus examined the feasibility and efficacy of additional chemotherapy in patients with recurrent MPM after EPP. METHODS: A retrospective review was conducted of 59 consecutive patients who underwent bi-/tri-modal treatment with induction chemotherapy, EPP, and radiation therapy from July 2004 to August 2013 at Hyogo College of Medicine (Nishinomiya, Japan). RESULTS: Of 59 patients, 39 (male/female = 31/8, right/left = 15/24, pathological stage I/II/III/IV = 1/7/23/3, bi-/tri-modality = 27/12) relapsed at a median age of 62 (range 37-71) years. The median time to recurrence after EPP was 11.6 months. Of the 39 relapsed patients, 12 received best supportive care alone, six started but discontinued chemotherapy, and the remaining 21 (53%) completed more than three cycles of intravenous chemotherapy. The median survival time after EPP was significantly longer in 21 patients who received additional chemotherapy than in 18 patients who did not (39.2 vs. 12.2 months, P = 0.009). CONCLUSIONS: Additional systemic chemotherapy was successfully administered in more than 50% of relapsed patients after bi-/tri-modal treatment, which included EPP, and resulted in a longer survival in comparison with best supportive care alone.
Authors: Loïc Lang-Lazdunski; Andrea Bille; Rohit Lal; Paul Cane; Emma McLean; David Landau; Jeremy Steele; James Spicer Journal: J Thorac Oncol Date: 2012-04 Impact factor: 15.609
Authors: C Manegold; J Symanowski; U Gatzemeier; M Reck; J von Pawel; C Kortsik; K Nackaerts; P Lianes; N J Vogelzang Journal: Ann Oncol Date: 2005-04-11 Impact factor: 32.976
Authors: Marc de Perrot; Ronald Feld; B C John Cho; Andrea Bezjak; Masaki Anraku; Ronald Burkes; Heidi Roberts; Ming S Tsao; Natasha Leighl; Shaf Keshavjee; Michael R Johnston Journal: J Clin Oncol Date: 2009-02-17 Impact factor: 44.544
Authors: Tom Treasure; Loic Lang-Lazdunski; David Waller; Judith M Bliss; Carol Tan; James Entwisle; Michael Snee; Mary O'Brien; Gill Thomas; Suresh Senan; Ken O'Byrne; Lucy S Kilburn; James Spicer; David Landau; John Edwards; Gill Coombes; Liz Darlison; Julian Peto Journal: Lancet Oncol Date: 2011-06-30 Impact factor: 41.316
Authors: Alice Bellini; Andrea Dell'Amore; Stefano Terzi; Giovanni Zambello; Andrea Zuin; Giulia Pasello; Fiorella Calabrese; Marco Schiavon; Federico Rea Journal: J Clin Med Date: 2021-03-08 Impact factor: 4.241